TacticScaleWhat Certara Does & How It Makes Money (CERT)
Updated October 2026 · reflects Certara's latest reported financials
Biosimulation software and services for faster, smarter drug development. It sells biosimulation, chemistry informatics, and regulatory software, including cloud-based platforms, to pharmaceutical and biotech companies.
How Certara makes money
It sells biosimulation, chemistry informatics, and regulatory software, including cloud-based platforms, to pharmaceutical and biotech companies. It also earns fees from technology-driven services such as model-informed drug development and regulatory submission support.
What Certara does
Certara, Inc., founded in 2008 and headquartered in Radnor, Pennsylvania, provides software and technology-driven services for biosimulation, which uses computer models to predict how drugs work in the body. Its best-known platforms are the Simcyp simulator for physiologically based pharmacokinetic modeling and the Phoenix suite (WinNonlin, NLME, and Phoenix cloud) for pharmacokinetic analysis and population modeling. It serves customers across the Americas, EMEA, and Asia Pacific. The company has also expanded beyond simulation. Its Chemaxon and D360 tools support chemistry and scientific informatics in early discovery. Pinnacle 21, CoAuthor, and GlobalSubmit handle clinical data standardization, regulatory writing, and submission management. Together, these products cover much of the drug development process, from discovery through regulatory approval and market access.
Products & services
- Simcyp Simulator
- Phoenix WinNonlin
- Phoenix NLME
- Pinnacle 21
- Chemaxon
- Certara D360
What is Certara worth?
On an owner-earnings DCF, Certara's most-likely value is about $9 versus a recent price near $9 (3% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$4) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Schrödinger (SDGR) · Arcus Biosciences (RCUS) · Charles River Laboratories International (CRL) · Pacira BioSciences (PCRX)